Core Viewpoint - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform, marking its entry into the consumer health sector [1] Group 1: Product Development - The two active ingredients developed are small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016), both of which have successfully passed the INCI registration in the United States [1] - The combined formulation product Groland has also received FDA registration, indicating regulatory approval for market entry [1] Group 2: Strategic Partnerships - Jingtai's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to $345 million, including several million dollars in upfront payments and milestone payments [1] - This partnership aims to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, utilizing Ailux's proprietary platform and AI antibody research capabilities [1] - This collaboration follows a previous $250 million agreement between Jingtai Technology and Eli Lilly for AI small molecule drug development [1]

Core Viewpoint - Jingtai Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform [1] Group 1: Product Development - The two developed molecules are small molecule Remeanagen (XTP-118) and peptide AquaKine (XTP-016), both of which have successfully passed the INCI registration in the US [1] - The combined formula product Groland has also received FDA registration, marking Jingtai's entry into the promising consumer health sector [1] Group 2: Strategic Partnerships - Jingtai's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to $345 million, including tens of millions in upfront payments and milestone payments [1] - Eli Lilly will utilize Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also leveraging its AI antibody research platform to enhance internal pipeline research [1] - This partnership follows a previous $250 million collaboration between Jingtai Technology and Eli Lilly for AI small molecule drug development earlier in 2023 [1]